Assessing the prevalence of Long COVID-19 in the Canary Islands
Long COVID: Evaluation of Physical and Functional Status
This study is trying to find out how many people in the Canary Islands have Long COVID-19 symptoms that last for more than 12 weeks after their COVID-19 infection.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Las Palmas de Gran Canaria Academic / other |
| Locations | 1 site (Las Palmas de Gran Canaria, Las Palmas) |
| Trial ID | NCT05228691 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prevalence of Long COVID-19 among individuals who have tested positive for COVID-19 in the Canary Islands. It will involve a cross-sectional descriptive approach, where patients experiencing symptoms for at least 12 weeks post-infection will undergo physical-functional evaluations conducted by trained physiotherapists. The study will utilize both self-completed questionnaires and assessments by evaluators to gather comprehensive data on the impact of Long COVID on patients' daily lives. Statistical analysis will be performed using IBM SPSS software to summarize and interpret the findings.
Who should consider this trial
Good fit: Ideal candidates include individuals who tested positive for COVID-19 and have experienced persistent symptoms for at least 12 weeks.
Not a fit: Patients with pre-existing comorbidities that mimic Long COVID symptoms, such as fibromyalgia or chronic fatigue, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Long COVID and improve post-acute care strategies for affected patients.
How similar studies have performed: Other studies have indicated the significant prevalence and impact of Long COVID, suggesting that this approach is relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have been positive for COVID-19 since the declaration of the state of alarm throughout the Spanish territory to deal with the health emergency situation caused by COVID-19 (March 14, 2020). * Symptoms associated with COVID-19 at least after 12 weeks of its detection. * Adequate cognitive and physical level to understand and perform the tests evaluation. Exclusion Criteria: * Present comorbidities prior to suffering from COVID-19 whose symptoms are resemble Post-acute COVID-19. * Fibromyalgia. * Chronic fatigue. * Neuromuscular disease. * Not having signed the informed consent. * Person undergoing treatment for active cancer.
Where this trial is running
Las Palmas de Gran Canaria, Las Palmas
- University of Las Palmas de Gran Canaria — Las Palmas de Gran Canaria, Las Palmas, Spain (Recruiting)
Study contacts
- Principal investigator: Aníbal Báez Suárez, PhD — University of Las Palmas de Gran Canaria
- Study coordinator: Aníbal Báez Suárez, PhD
- Email: anibal.baez@ulpgc.es
- Phone: +34652077692
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.